



## **Tilray® Boosts International Export Capacity with Manufacturing License and GMP Certification at EU Campus**

May 23, 2019

***Licensing and certification enhances company's capacity to export medical cannabis from Portugal to Germany, other EU member states and international markets***

NANAIMO, British Columbia--(BUSINESS WIRE)--May 23, 2019-- Tilray, Inc. ("Tilray" or "the Company") (NASDAQ:TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced that its wholly-owned subsidiary Tilray Portugal Unipessoal Lda. ("Tilray Portugal") has received a standard manufacturing license and a Good Manufacturing Practices (GMP) certification, in accordance with the European Medicines Agency's (EMA) standards, for its Biocant Park manufacturing facility in Cantanhede, Portugal. This license and certification allow Tilray Portugal to manufacture and export GMP-certified dried cannabis as an active substance for medicinal products.

This press release features multimedia. View the full release here: <https://www.businesswire.com/news/home/20190523005139/en/>

Tilray has established sales and distribution arrangements to supply medical cannabis through major pharmaceutical distribution channels throughout Germany and the European Union (EU). This license and certification further enhances Tilray's capacity to serve international markets such as Germany and other EU member states, as well as non-EU jurisdictions that recognize EU GMP certification.

Tilray's EU Campus in Portugal is a multi-faceted production facility that includes indoor, outdoor and greenhouse cultivation sites; research and quality control labs; as well as processing, packaging and distribution sites for medical cannabis and cannabinoid-containing medical products. To date, Tilray has invested approximately €20 million in the facility, which totals nearly 250,000 square feet with additional room to expand. The site also serves as a hub supporting Tilray's clinical research and product development efforts across Europe. The Tilray EU Campus currently employs over 100 people, and that number is expected to double by the end of 2019, with production ramping up and multiple harvests anticipated in the coming months. An official ribbon-cutting ceremony celebrating the inauguration of Tilray's EU Campus was hosted in April 2019.

"This licensing and certification marks a critical milestone for our growth in Portugal and Europe. We're proud to increase our international export capacity and are looking forward to exporting dried cannabis as active substances from our EU Campus to legal jurisdictions in the EU and other international markets," said Sascha Mielcarek, Managing Director, Europe. "The next phase of GMP certification will allow us to utilize the full capacity of our multi-faceted facility and continue to serve more patients in-need."

Tilray was the first medical cannabis producer to successfully import medical cannabis products into the EU and the first licensed medical cannabis producer in North America to obtain GMP certification in accordance with EMA standards. Tilray expects the second phase of GMP certification for its facility in Portugal to occur in the coming months, which will allow the company to manufacture and export GMP-certified finished medicinal products from Portugal to international markets.

### **About Tilray®**

Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in 12 countries spanning 5 continents.



**Cautionary note regarding forward-looking statements:**

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements or forward-looking information in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, including without limitation statements in respect to Tilray’s intention to increase production, processing, cultivation or R&D capacity or launch brands, products and novel form factors at any of its facilities and Tilray’s expectations relating to servicing the global cannabis market. Forward-looking statements are not a guarantee of future performance and are based upon a

number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment and future approvals and permits. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements and they are not guarantees of future results. Please see the heading “Risk Factors” in Tilray’s Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission and Canadian securities regulators on May 15, 2019, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements. Tilray does not undertake and specifically declines any obligation to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190523005139/en/>

Source: Tilray, Inc.

Media: Chrissy Roebuck, +1-833-206-8161, [news@tilray.com](mailto:news@tilray.com)

Investors: Katie Turner, +1-646-277-1228, [Katie.turner@icrinc.com](mailto:Katie.turner@icrinc.com)